In the phase II study (NCT03785249) of this agent for patients with KRAS G12C mutant NSCLC previously treated with PD‐1/PD‐L1 antibody and platinum‐based chemotherapy, the ORR reached 42.9% and the median DOR was 8.5 months. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.